These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35232288)

  • 1. Accounting for the rarity of the disease when designing clinical trials with a focus on pediatric cancers.
    Mauguen A
    Clin Trials; 2022 Jun; 19(3):292-296. PubMed ID: 35232288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
    Ji Z; Lin J; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification or simulation: Power calculation in clinical trials.
    Huang C; Li P; Martin CR
    Contemp Clin Trials; 2022 Feb; 113():106663. PubMed ID: 34958933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of simple and accessible methods for meta-analysis involving rare events: A simulation study.
    Hodkinson A; Kontopantelis E
    Stat Methods Med Res; 2021 Jul; 30(7):1589-1608. PubMed ID: 34139915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the analysis of composite endpoints in rare disease trials.
    McMenamin M; Berglind A; Wason JMS
    Orphanet J Rare Dis; 2018 May; 13(1):81. PubMed ID: 29788976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing efficient randomized trials: power and sample size calculation when using semiparametric efficient estimators.
    Schuler A
    Int J Biostat; 2021 Aug; 18(1):151-171. PubMed ID: 34364314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power analysis for idiographic (within-subject) clinical trials: Implications for treatments of rare conditions and precision medicine.
    Tueller S; Ramirez D; Cance JD; Ye A; Wheeler AC; Fan Z; Hornik C; Ridenour TA
    Behav Res Methods; 2023 Dec; 55(8):4175-4199. PubMed ID: 36526885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small sample performance of bias-corrected sandwich estimators for cluster-randomized trials with binary outcomes.
    Li P; Redden DT
    Stat Med; 2015 Jan; 34(2):281-96. PubMed ID: 25345738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trials.
    Reichmann WM; LaValley MP; Gagnon DR; Losina E
    BMC Med Res Methodol; 2013 Feb; 13():21. PubMed ID: 23414513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to sample size calculation for clinical trials in rare diseases.
    Miller F; Zohar S; Stallard N; Madan J; Posch M; Hee SW; Pearce M; Vågerö M; Day S
    Pharm Stat; 2018 May; 17(3):214-230. PubMed ID: 29322632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.
    Mi MY; Betensky RA
    Clin Trials; 2013 Apr; 10(2):207-15. PubMed ID: 23283576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Handling Poor Accrual in Pediatric Trials: A Simulation Study Using a Bayesian Approach.
    Azzolina D; Lorenzoni G; Bressan S; Da Dalt L; Baldi I; Gregori D
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33669985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data.
    Jackson CL; Colborn K; Gao D; Rao S; Slater HC; Parikh S; Foy BD; Kittelson J
    Clin Trials; 2021 Oct; 18(5):582-593. PubMed ID: 34218684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential design with boundaries approach in pediatric intervention research reduces sample size.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2010 Jan; 63(1):19-27. PubMed ID: 19788954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power.
    Khan I; Sarker SJ; Hackshaw A
    Br J Cancer; 2012 Nov; 107(11):1801-9. PubMed ID: 23169334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world scenarios in rare variant association analysis: the impact of imbalance and sample size on the power in silico.
    Zhang X; Basile AO; Pendergrass SA; Ritchie MD
    BMC Bioinformatics; 2019 Jan; 20(1):46. PubMed ID: 30669967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and analysis features used in small population and rare disease trials: A targeted review.
    Partington G; Cro S; Mason A; Phillips R; Cornelius V
    J Clin Epidemiol; 2022 Apr; 144():93-101. PubMed ID: 34910979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.